No Data
Brookline Capital Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $9
Quince Therapeutics Files Mixed Securities Shelf; Shares Rise After Hours
Express News | Quince Therapeutics: Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Brookline Capital Initiates Coverage On Quince Therapeutics With Buy Rating, Announces Price Target of $9
Quince Therapeutics Analyst Ratings